Investors
EASTGATE BIOTECH PROVIDES CORPORATE UPDATE
March 1, 2018
The Company’s strategic moves over the past year to improve its underlying operations were part of a corporate vision to be a “disrupter” in the drug delivery sector targeting unmet medical needs. As a company we collectively agreed that drug development requires patience and funding and we had a realization that the burn rate needed to be curbed. The time between drug development milestones can test investor’s patience so we were opportunistic in our purchase of OMNI S
Read moreEastGate Biotech Announces Annual Report Form 10-K Filing
March 1, 2018
Toronto, ON, February 28th, 2018 – EastGate Biotech (OTC BB: ETBI) a market leading pharmaceutical technology company, today announced that it filed an Annual Report on Form 10-K under the U.S. Securities Exchange Act of 1934 for EastGate Biotech for the period through December 31, 2017 (“Form 10-K”) with the U.S. Securities Exchange Commission (the “SEC”) on 27 February 2018. The Form 10-K can be found on the SEC’s website at www.sec.gov.
Read moreEASTGATE BIOTECH ANNOUNCES OPENING OF REPRESENTATIVE OFFICE IN THE PHILIPPINES
January 29, 2018
The representative office, located in Metro Manila will be identified as EastGate Biotech Pharmaceuticals Philippines incorporated in November, 2017. In addition to providing a legal presence the office will allow EastGate Biotech to position itself in the rapidly growing and vibrant Asian healthcare market by increasing the profile of the company within this market. It will be staffed by Roger Munoz, the company’s local agent, who will serve as the Managing Director. The office will also support and coordinate all regulatory activities and serve as a hub from which EastGate management and personnel will engage its partnership strategies and new business development.
Read moreGunpowder Capital Corp. Provides Update on EastGate
December 11, 2017
Gunpowder Capital Corp. (CSE-GPC) announced today that it continues to work with its client EastGate Biotech Corp. (OTC Pink-ETBI).
Read moreEASTGATE BIOTECH ANNOUNCES ENGAGEMENT OF THE KELL GROUP LIMITED FOR INTRODUCTION TO VARIOUS SOURCES OF FUNDING FOR COMPANY INITIATIVES
August 30, 2017
“We are pleased to be working with a group that has a long standing reputation with a wide financial network," said Anna Gluskin, CEO of EastGate. “We are looking forward to moving into an exciting stage with some of our developments that have different requirements and funding strategies for which we believe The Kell Group Limited is best suited to assist in these plans and we hope will increase their shareholding position in the company”, concludes Gluskin.
Read moreEASTGATE BIOTECH’S RECENT ACQUISITION, OMNI SURGERY + ANTI-AGING CENTRE, PRESENTS THE OMNI SCHOOL OF MEDICAL ESTHETICS.
May 30, 2017
The mission statement of the OMNI School of Medical Esthetics is to ensure quality delivery of care while utilizing the latest techniques and technology. The program has two parts
Read moreEASTGATE BIOTECH CORP. ENGAGES A NEW INDEPENDENT AUDITOR
May 16, 2017
Eastgate pharmaceutical and biotech research company that develops, produces and distributes innovative and healthy nutraceuticals and pharmaceutical developments has announced today that it had selected Anton & Chia LLP as its new independent auditing firm.
Read moreEASTGATE BIOTECH ENGAGES AGENT TO IDENTIFY SUITABLE JOINT VENTURE PARTNERS AND SUPPLIERS IN THE PHILIPPINES
May 15, 2017
The agent, Roger Munoz, a principal of i-Power Philippines, a subsidiary of the ICube Group (www.icube.ph) a large holding group mostly for Nippon SME business in the Philippines, will work together with the company’s own Global Business Development team to act in EastGate’s interests
Read moreEastgate Biotech Business Turnaround Expert Bill Abajian On The Positive Stocks Investor Influence Network
April 29, 2017
Mr. William (Bill) D. Abajian brings over 30 years experience in the pharmaceutical and biotechnology industry. He started his career at Electro Nucleonics Inc. in Fairfield, New Jersey where he served as the Vice President of Sales and Marketing between 1981-1988.
Read moreEastgate Biotech Corp., Engages Gunpowder Capital Corp.
April 25, 2017
Toronto, Ontario, April 25th, 2017 – Gunpowder Capital Corp., (CSE: GPC), (CSE: GPC.PR.A), (Frankfurt: YS6N), (“Gunpowder”, “GPC” or the “Corporation”) announced today that entered into various agreements with Eastgate Biotech Corp., (OTCPink: ETBI) (“Eastgate”).
Read more